Table of contents

Strange how all these corporate interests are clamouring to inject your children with their gene-therapies. And will in-fact try to use EUA for all future treatments. Oh, and there will be "many many more" in the future. And no liability. Great right? For gavi and the industries behind it yes.

Ivermectin Docks to the SARS-CoV-2 Spike Receptor-binding Domain Attached to ACE2
Background/Aim: Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). One drug that has attracted interest is the antiparasitic compound ivermectin, a macrocyclic lactone derived ...
The researchers showed how ivermectin interferes with the attachment of the spike protein to the human cell membrane

Get it, get your weight, calculate the dose, and give to your "dog"

Ivermectin for COVID-19: real-time meta analysis of 58 studies
Ivermectin for COVID-19. Early treatment - 78% improvement, p < 0.0001. All studies - 71% improvement, p < 0.0001. 1 in 9 trillion probability results of the 58 studies are from an ineffective treatment (p = 1.1e-13).

If you believe the WHO and FDA have no vested interest in the current vaccination program, then you are naive beyond words.

The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial
Among patients with non-severe COVID-19 and no risk factors for severe disease receivinga single 400 mcg/kg dose of ivermectin within 72 h of fever or cough onset there wasno difference in the proportion of PCR positives. There was however a marked reductionof self-reported anosmia/hyposmia, a re…
Among patients with non-severe COVID-19 and no risk factors for severe disease receiving a single 400 mcg/kg dose of ivermectin within 72 h of fever or cough onset there was no difference in the proportion of PCR positives. There was however a marked reduction of self-reported anosmia/hyposmia, a reduction of cough and a tendency to lower viral loads and lower IgG titers which warrants assessment in larger trials.

But of course, the EMA and WHO advise not to use it because of a lack of studies... So do large scale study.. no, we have vested interest in the current vaccines program.

EMA therefore concluded that use of ivermectin for prevention or treatment of COVID-19 cannot currently be recommended outside controlled clinical trials. Further well-designed, randomised studies are needed to draw conclusions as to whether the product is effective and safe in the prevention and treatment of COVID-19.
WHO advises that ivermectin only be used to treat COVID-19 within clinical trials
The current evidence on the use of ivermectin to treat COVID-19 patients is inconclusive. Until more data is available, WHO recommends that the drug only be used within clinical trials.

Vested Interests

No no, we want our money, our pound of your flesh. And then later well apologise if you were affected by one of our "really really rare side-effects". Or maybe not.

EMA Approves Expanded COVID Vaccine Manufacturing Capacity For Europe; India Interrupts COVAX Vaccine Deliveries To Low Income Countries - Health Policy Watch
The European Medicines Agency (EMA) has officially authorized expanded capacity in three new vaccine manufacturing facilities on the continent producing
The World Health Organization
WHO is one of four permanent members of the Gavi Board.
Press corner
Highlights, press releases and speeches
The EU has been a donor to the GAVI Alliance since 2003. The Alliance's mission is closely aligned with the EU's development policy to reduce poverty and help reach the Millennium Development Goals (MDGs) by 2015. GAVI Alliance support complements direct and regional support provided by European Institutions to partner countries.

Even the G20 wants its pound of flesh

G20 leaders to back COVID-19 vaccine voluntary licensing, no patent waiver
Leaders of the world’s largest economies will adopt on Friday a declaration recommending voluntary actions to boost COVID-19 vaccine production, snubbing a push from the United States and other nations on patent waivers, the final text shows.
The EU executive, which co-hosts the summit with the Italian government, is set to announce it will set up three manufacturing hubs in Africa this year to boost long-term production of vaccines, one EU official told Reuters.

Nothing to see there, just setting up industry around making this stuff.

COVID-19 vaccination disparity raises vexed questions of ethics and economics
Pandemic unlikely to be considered over until a suitably large proportion of the world’s population is vaccinated

And here we are trying to setup Emergency Use Authorisations EUA for all future vaccines. Can you see the plot yet?

How emergency use authorisations could accelerate access to COVID-19 vaccines
Emergency use procedures are designed to make potentially life-saving medical products available as quickly as possible during health emergencies. A record number have been granted since the arrival of COVID-19 pandemic, but what does this mean for countries in the global South?